Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

被引：0
作者：
F. J. Lavalle-González
A. Januszewicz
J. Davidson
C. Tong
R. Qiu
W. Canovatchel
G. Meininger
机构：
[1] Universidad Autonóma de Nuevo León,Endocrinology and Internal Medicine Department
[2] Institute of Cardiology,Department of Hypertension
[3] University of Texas Southwestern Medical School,Department of Medicine
[4] Janssen Research & Development,undefined
[5] LLC,undefined
来源：
Diabetologia | 2013年 / 56卷
关键词：
Canagliflozin; Metformin; Sitagliptin; Sodium glucose co-transporter 2 (SGLT2) inhibitor; Type 2 diabetes mellitus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2582 / 2592
页数：10
相关论文
共 50 条
  • [21] Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America
    Lavalle-Gonzalez, Fernando J.
    Eliaschewitz, Freddy G.
    Cerdas, Sonia
    Del Pilar Chacon, Maria
    Tong, Cindy
    Alba, Maria
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (03) : 427 - 439
  • [22] Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
    Barzilai, Nir
    Guo, Hua
    Mahoney, Erin M.
    Caporossi, Suzanne
    Golm, Gregory T.
    Langdon, Ronald B.
    Williams-Herman, Debora
    Kaufman, Keith D.
    Amatruda, John M.
    Goldstein, Barry J.
    Steinberg, Helmut
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (05) : 1049 - 1058
  • [23] Safety and Efficacy of Sitagliptin-Metformin in Fixed Combination for the Treatment of Type 2 Diabetes Mellitus
    Ballav, Chitrabhanu
    Gough, Stephen C. L.
    CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES, 2013, 6 : 25 - 37
  • [24] Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial
    Arechavaleta, R.
    Seck, T.
    Chen, Y.
    Krobot, K. J.
    O'Neill, E. A.
    Duran, L.
    Kaufman, K. D.
    Williams-Herman, D.
    Goldstein, B. J.
    DIABETES OBESITY & METABOLISM, 2011, 13 (02) : 160 - 168
  • [25] Efficacy and safety of fixed dose combination of Sitagliptin, metformin, and pioglitazone in type 2 Diabetes (IMPACT study): a randomized controlled trial
    Mondal Aashish
    Naskar Arindam
    Sheelu Shafiq Siddiqi
    Deepak Bhosle
    V. J. Mallikarjuna
    Dange Amol
    Sorate Sanket
    Gavali Omkar
    Patel Parth
    Hasnani Dhruvi
    Prasad Durga
    Dalwadi Pradeep
    Kumar Suresh
    Pathak Vaishali
    Chaudhari Mayura
    Basu Indraneel
    Shembalkar Jayashri
    Fariooqui Arif
    S. K. Raghavendra
    Varade Deepak
    Thakkar Ravindra
    Bhanushali Shaishav
    Gaikwad Vijay
    Kamran Khan
    V. V. Mahajani
    A. D. Sharma
    Mayur Mayabhate
    R. R. Pawar
    A. S. Aiwale
    Shahavi Vinayaka
    Clinical Diabetes and Endocrinology, 10 (1):
  • [26] Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy
    Kadowaki T.
    Tajima N.
    Odawara M.
    Minamide T.
    Kawashima M.
    Yanagida D.
    Okamoto T.
    Arjona Ferreira J.C.
    Diabetology International, 2013, 4 (3) : 160 - 172
  • [27] Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy
    Yamout, Hala
    Perkovic, Vlado
    Davies, Melanie
    Woo, Vincent
    de Zeeuw, Dick
    Mayer, Cristiana
    Vijapurkar, Ujjwala
    Kline, Irina
    Usiskin, Keith
    Meininger, Gary
    Bakris, George
    AMERICAN JOURNAL OF NEPHROLOGY, 2014, 40 (01) : 64 - 74
  • [28] Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus
    Qiu, Rong
    Capuano, George
    Meininger, Gary
    JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY, 2014, 1 (02) : 54 - 60
  • [29] Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes
    Dobs, Adrian S.
    Goldstein, Barry J.
    Aschner, Pablo
    Horton, Edward S.
    Umpierrez, Guillermo E.
    Duran, Lorraine
    Hill, Julie S.
    Chen, Yu
    Golm, Gregory T.
    Langdon, Ronald B.
    Williams-Herman, Debora E.
    Kaufman, Keith D.
    Amatruda, John M.
    Ferreira, Juan Camilo Arjona
    JOURNAL OF DIABETES, 2013, 5 (01) : 68 - 79
  • [30] Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial
    Fulcher, Greg
    Matthews, David R.
    Perkovic, Vlado
    de Zeeuw, Dick
    Mahaffey, Kenneth W.
    Weiss, Robert
    Rosenstock, Julio
    Capuano, George
    Desai, Mehul
    Shaw, Wayne
    Vercruysse, Frank
    Meininger, Gary
    Neal, Bruce
    DIABETES THERAPY, 2015, 6 (03) : 289 - 302
12345